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The American Cancer Society estimates that there will be more than 1.5 million new cases
of cancer in 2011, underscoring the need for identiﬁcation of new therapeutic targets and
development of novel cancer therapies. Previous studies have implicated the human aldo-
ketoreductases AKR1B1 and AKR1B10 in cancer, and therefore we examined AKR1B1
and AKR1B10 expression across all major human cancer types using the Oncomine can-
cer gene expression database (Compendia Biosciences, www.oncomine.com). Using this
database, we found that expression of AKR1B1 and AKR1B10 varies greatly by cancer
type and tissue of origin, including agreement with previous reports that AKR1B10 is
signiﬁcantly over-expressed in cancers of the lungs and liver. AKR1B1 is more broadly
over-expressed in human cancers than AKR1B10, albeit at a generally lower magnitude.
AKR1B1 over-expression was found to be associated with shortened patient survival in
acute myelogenous leukemias and multiple myelomas. High AKR1B10 expression tends
to predict less aggressive clinical course generally, notably within lung cancers, where it
tends to be highly over-expressed compared to normal tissue.These ﬁndings suggest that
AKR1B1 inhibitors in particular hold great potential as novel cancer therapeutics.
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INTRODUCTION
Cancer is the second leading cause of death in the U.S. behind
heart disease, and theAmericanCancer Society estimates that there
will be more than 1.5 million new cases of cancer in 2011. While
improvements in detection, treatment, and prevention have led to
decreases in cancer deaths and incidence for many cancer types in
the U.S., the incidence rate for some cancers such as hepatocellu-
lar carcinoma is still rising. However, as the U.S. population ages,
cancer incidence may reach a plateau or even rebound. There-
fore, identiﬁcation of new therapeutic targets and development
of novel cancer therapies is still a pressing need. Previous stud-
ies have shown that the human aldo-ketoreductase AKR1B10 is
over-expressed in cancers of the liver and lungs (Fukumoto et al.,
2005; Woenckhaus et al., 2006; Heringlake et al., 2010; Kang et al.,
2011; Schmitz et al., 2011) while AKR1B10 and the related enzyme
AKR1B1 are both linked to drug resistance in cancer-derived cell
lines (Dan et al., 2003; Plebuch et al., 2007; Matsunaga et al., 2011;
Zhong et al., 2011). Several published studies have also pointed
to role for AKR1B1 in colon carcinogenesis (Tammali et al., 2009,
2011a,b; Ramana et al., 2010). As well-characterized inhibitors
for these enzymes are already in use or development, they would
seem to be attractive targets for cancer therapeutic development.
However, these studies have been conducted largely in model sys-
tems, and thus there is very little known about the involvement
of AKR1B10 in cancer outside of the lungs and liver, and while
AKR1B1 expression has been reported to be elevated in human
cancers, this study was limited by a small number of available
patient samples (Saraswat et al., 2006). Since AKR1B1 has been
shown to be involved in many cellular processes relevant to cancer
such as EMT (Zablocki et al., 2011), inﬂammation (Yadav et al.,
2007, 2009, 2011), and angiogenesis (Tammali et al., 2011b,c), and
AKR1B10 is known to have relevance to human cancers, we exam-
ined AKR1B1 and AKR1B10 expression across all major human
cancer types using the Oncomine cancer gene expression database
(Compendia Biosciences, www.oncomine.com).
Using this database, we found that expression of AKR1B1 and
AKR1B10 varies greatly by cancer type and tissue of origin, includ-
ing agreement with previous reports that AKR1B10 is signiﬁcantly
over-expressed in cancers of the lungs and liver (Fukumoto et al.,
2005; Woenckhaus et al., 2006; Heringlake et al., 2010; Kang et al.,
2011; Schmitz et al., 2011). While under-expression of AKRs in
human cancers is less common than over-expression, AKR1B1
appears to be generally under-expressed in prostate cancers com-
pared to normal tissue while AKR1B10 expression is reduced in
colon tumors.AKR1B1 over-expression was associated with short-
ened patient survival in acute myelogenous leukemias and mul-
tiple myelomas. High AKR1B10 expression tends to predict less
aggressive clinical course generally, notably within lung cancers,
where it tends to be highly over-expressed compared to normal
tissue. Neither AKR1B1 nor AKR1B10 appears to have notable
associations with disease recurrence, and their associations with
the presence of metastases are inconsistent.
These ﬁndings suggest that AKR1B1 in particular may be a
promising drug target, due to its broad over-expression in solid
tumors and leukemias. Previous drug development attempts cen-
tered on AKR1B1 inhibition in non-cancer disease states were
halted due to unacceptable toxicity; however, the reported tox-
icities were milder than other chemotherapeutics currently in
use. Newer AKR1B1 inhibitors such as those derived from nat-
ural products (Suryanarayana et al., 2004, 2007; Saraswat et al.,
www.frontiersin.org June 2012 | Volume 3 | Article 104 | 1
Lafﬁn and Petrash AKR1B1 in cancer
2008) may have lower toxicity than earlier compounds, and there-
fore hold great potential as novel therapeutics for cancers where
AKR1B1 tends to be over-expressed.
MATERIALS AND METHODS
Meta-analysis ofAKR1B1 andAKR1B10 gene expression inhuman
cancers and normal tissues as well as related statistical analy-
sis were conducted using the Oncomine gene expression data-
base (www.oncomine.com, Compendia biosciences, Ann Arbor,
MI, USA). Where appropriate, raw data was downloaded from
Oncomine and scrutinized to ensure consistent comparisons and
deﬁnitions such as “high grade”were used across different studies.
For example, in prostate tumors “high gleason score” is deﬁned by
the highest grade tumors within the study being considered,which
for some studies is GS7 and in others GS10. P-values were deter-
mined by Student’s t -test and those less than 0.05 were considered
signiﬁcant. Gene rank represents the ordered numerical rank of
that gene’s p-value against all other genes for that comparison– i.e.,
a gene with a rank of 5 has a more signiﬁcant difference in expres-
sion level for the two conditions examined than for all but four
other genes. In data presented considering over-expression versus
under-expression in a given cancer type, the most signiﬁcant p-
value and gene rank are presented even in cases where neither were
signiﬁcant as deﬁned by p< 0.05. Only studies based on human
clinical samples were included in our analyses. Where an “overall
p-value” is listed, the p-value generated by simultaneously consid-
ering all available data within Oncomine for the given comparison
is displayed, i.e., the overall p-value for the cancer versus nor-
mal comparisons listed in Table 1 includes all studies for which
gene expression for cancerous and corresponding normal tissue
was available within Oncomine. Median gene ranks displayed are
similarly inclusive of all available data in Oncomine. All graph-
ics displayed in ﬁgures are Oncomine.svg ﬁle output modiﬁed by
Adobe Illustrator.
RESULTS
To determine whether the aldo-ketoreductases AKR1B1 and
AKR1B10 were differentially expressed between cancerous and
normal tissues,we broadly examinedmicroarray data frompatient
samples contained within the Oncomine database. Results from
cancer types where a statistically signiﬁcant difference in AKR
expression between the cancerous and corresponding normal tis-
sue exists are summarized in Table 1. The cancers where gene
expression for AKRs was compared to the corresponding normal
tissue, but no overall signiﬁcant difference was found were cer-
tain brain tumors (oligodendrogliomas, mixed gliomas), ductal
and lobular breast cancers, acute myeloid leukemias, myelomas,
and ovarian cancers (not shown). Data for cancers where only
one study was available for analysis is also not shown. AKR1B1
expression is signiﬁcantly elevated compared to the corresponding
normal tissue in bladder, brain (astrocytomas and glioblastomas),
cervical, esophageal, head and neck, kidney, leukemias (T-cell
acute, B-cell acute, and chronic), lymphomas, and melanomas
(Table 1; Figure 1A). The fold change in gene expression ver-
sus the normal tissue is summarized by study in Table 1, with
AKR1B1 expression ranging from∼1.2- to 5-fold thenormal tissue
in the majority of cancers where it is signiﬁcantly over-expressed.
The most signiﬁcant differences between AKR1B1 expression in
cancerous and normal tissue are seen in leukemias (Table 1;
Figure 1A). AKR1B1 expression is signiﬁcantly lower than the
corresponding normal tissue in prostate cancers (Table 1). As pre-
viously reported, AKR1B10 is over-expressed in liver and lung
tumors (Table 1; Fukumoto et al., 2005; Woenckhaus et al., 2006;
Heringlake et al., 2010; Kang et al., 2011; Schmitz et al., 2011),
with fold change relative to normal tissue ranging from 12- to
67-fold in liver cancers; 2- to 75-fold in squamous cell lung can-
cers; and 1.5- to 5.5-fold in lung adenocarcinomas (Table 1).
AKR1B10 is also signiﬁcantly over-expressed in leukemias (T-cell
acute, B-cell acute, and chronic) and pancreatic cancers (Table 1;
Figure 1A). AKR1B10 over-expression thus appears to be less
common than AKR1B1 over-expression in cancer, and AKR1B10
is under-expressed in colon, gastric, and head and neck cancers
(Table 1). It should be noted that these associations are those that
hold true across the studies contained within Oncomine, and mul-
tiple studies may have individually held a signiﬁcant association of
AKR expression with either the cancerous or normal state, but not
in the broader comparison. Our methods also necessarily exclude
studies not contained within the Oncomine database.
As shown in Figure 1, even for leukemia types in which
AKRs are over-expressed compared to normal tissue at a high
level of statistical signiﬁcance, there is considerable heterogeneity
amongst patients in terms of AKR1B1 and AKR1B10 expression
(Figure 1A). This led us to ask whether AKR expression could
identify certain types of patients within these leukemias, and
we found that high levels of AKR1B1 expression within B-cell
leukemia patients was strongly associated with the presence of the
TCF3-PBX1 gene fusion (Figure 1B), while under-expression of
AKR1B1 in chronic myelogenous leukemias was associated with
the presence of the PML-RARA gene fusion (Figure 1C). Across
all translocations and gene fusions in all leukemia types, AKR1B1
over-expression is associatedwith the TCF3-PBX1 gene fusion and
11q23 MLL rearrangements, while under-expression is associated
with the PML-RARA and ETV6-RUNX1 gene fusions (Figure 2).
Other gene fusions, translocations, and point mutations exam-
ined in leukemias did not have a statistically signiﬁcant, consistent
pattern (Figure 2 and data not shown).
We next asked whether expression of AKRs might be able to
predict clinical outcome, speciﬁcally in terms of patient survival,
disease recurrence, tumor grade, and metastasis. We found no sig-
niﬁcant associations with expression of AKR1B1 and the presence
of metastasis, tumor grade,orwithdisease recurrence in any cancer
type, though some individual studies sometimes contained a sig-
niﬁcant relationship that didnot holdupwhenall available data for
that cancer type was considered (data not shown). AKR1B1 over-
expression was associated with decreased patient survival at 1 year
post-prognosis in acute myeloid leukemias (Figure 3A), as well
as decreased patient survival at 1 year post-prognosis in multiple
myeloma (Figure 3B). AKR1B1 over-expression was also associ-
ated with decreased survival in pancreatic cancer, however, only
one small study (27 patients) within Oncomine contained patient
survival data (data not shown). While no signiﬁcant associations
of patient survival with AKR1B10 expression were observed, it
is noteworthy that in the solid tumors where AKR1B10 is most
highly over-expressed, namely liver cancer and squamous cell lung
carcinoma, there is a strong trend for AKR1B10 over-expression
predicting longer patient survival (Figure 3C).
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Table 1 | AKR expression in human cancers.
Gene Cancer type Mean fold change(s) versus normal tissue, by study Overall p-value Median gene rank
AKR1B1 Bladder (inﬁltrating) 1.77, 1.26, 1.09 0.007 3659
AKR1B10 Bladder (inﬁltrating) 1.18, −1.80, −2.61, −3.72 0.107 2596
AKR1B1 Brain (astrocytomas) 2.31, 1.96, 1.96, 1.39, 1.27, 1.22 0.002 374.5
AKR1B10 Brain (astrocytomas) 1.12, −1.28, −1.27, −1.27, −1.09 0.074 5854
AKR1B1 Brain (glioblastomas) 2.15, 1.31, 1.23, 1.21, −1.64 0.002 5624
AKR1B10 Brain (glioblastomas) 1.46, 1.07, 1.02, −1.18, −1.00 0.421 7509
AKR1B1 Cervical 2.90, 2.12, 2.09, 1.14 1.32E-06 1152.5
AKR1B10 Cervical 1.09, −6.97, −5.30, −1.10 0.256 5532
AKR1B1 Colon 1.07, −1.50, −1.28, −1.12, −1.12, −1.06, −1.05, −1.04 0.118 4914
AKR1B10 Colon −30.67, −15.31, −12.80, −10.60, −7.25, −1.47, −1.41 2.97E-09 252
AKR1B1 Esophageal 4.52, 2.99, 1.88, 1.54, 1.29 9.19E-04 3294
AKR1B10 Esophageal 1.68, 1.09, -3.17, −2.22, −2.02, −1.79 0.118 4784.5
AKR1B1 Gastric 1.18, 1.06, 1.04 0.116 8244
AKR1B10 Gastric −8.15, −4.61 0.001 469
AKR1B1 Head and neck 2.61, 1.77, 1.76, 1.41 4.44E-04 619.5
AKR1B10 Head and neck −5.01, −2.19, −2.07, −1.10 0.043 2276.5
AKR1B1 Kidney 3.11, 3.00, 2.85, 2.59, 2.42, 2.01, 1.90 3.61E-05 938.5
AKR1B10 Kidney 5.11, 1.73, 1.54, 1.01, −1.71, −1.35 −1.09 0.257 7125.5
AKR1B1 Leukemia (B-cell acute) 5.32, 2.39, 2.31, 1.92 6.95E-36 600
AKR1B10 Leukemia (B-cell acute) 3.38, 1.11, 1.08, 1.06 8.30E-06 5014.5
AKR1B1 Leukemia (T-cell acute) 4.52, 1.52, -1.02 1.91E-13 2762
AKR1B10 Leukemia (T-cell acute) 3.09, 1.05, −1.21 0.006 7632
AKR1B1 Leukemia (chronic) 1.27, 1.26, −1.48 1.47E-09 4993
AKR1B10 Leukemia (chronic) 1.07, −2.60, −1.23 6.02E-05 6924
AKR1B1 Liver 2.19, 1.28, 1.22, 1.09 0.066 5007.5
AKR1B10 Liver 66.99, 20.82, 14.49, 12.68 1.75E-11 366
AKR1B1 Lung (adenocarcinoma) 1.02, -2.43, −1.25, −1.19, −1.10, −1.08 0.374 4551
AKR1B10 Lung (adenocarcinoma) 5.62, 3.28, 2.58, 1.92, 1.57 4.90E-04 3068
AKR1B1 Lung (squamous) 1.42, -1.24, −1.11, −1.06 0.593 5655.5
AKR1B10 Lung (squamous) 74.71, 66.92, 34.11, 2.03 0.001 483
AKR1B1 Lymphoma 1.86, 1.33, 1.26 0.016 2006
AKR1B10 Lymphoma 1.08, −1.49, −1.22 0.116 5095
AKR1B1 Melanoma 2.43, 1.74, 1.03 0.006 1394
AKR1B10 Melanoma 1.01, 1.01, −1.48 0.266 8928
AKR1B1 Pancreatic 1.74, 1.74, 1.43, 1.41, 1.35, 1.33, 1.17, −2.47 0.069 2479.5
AKR1B10 Pancreatic 13.62, 5.32, 3.21, 2.91, 1.95, −2.56, −1.59 0.003 3600
AKR1B1 Prostate −1.75, −1.71, −1.58, −1.53, −1.52, −1.48, −1.48, −1.45, −1.41,
−1.37, −1.35, −1.31, −1.25, −1.17
0.01 667.5
AKR1B10 Prostate 1.61, 1.3, 1.16, 1.14, 1.05, 1.01, 1.00, -2.20, −1.55, −1.38, −1.03 0.878 5846
Expression of AKR1B1 and AKR1B10 mRNA was examined in all tumor types and hematological malignancies contained within the Oncomine database. Displayed
in this table are the average fold changes for each study analyzed, overall p-value, and median gene rank for all cancer types where the overall p-value was signiﬁcant
for either under-expression (blue) or over-expression (red) of either AKR gene examined.
DISCUSSION
In this report we show that AKR1B1 and AKR1B10 are
over-expressed, and less frequently under-expressed, in a
cancer-type-speciﬁc manner. AKR1B10 is most prominently up-
regulated in cancers of the liver and lungs, consistent with pre-
vious reports (Fukumoto et al., 2005; Woenckhaus et al., 2006;
Heringlake et al., 2010; Kang et al., 2011; Schmitz et al., 2011).
AKR1B1 over-expression is more common amongst different
tumor types than AKR1B10 over-expression, but at a generally
lower magnitude (Table 1). Under-expression is less common for
either AKR, with AKR1B1 under-expressed in prostate tumors
and AKR1B10 under-expressed in colon and head and neck can-
cers (Table 1). Increased AKR1B1 expression is also associated
with the TCF3-PBX1 gene fusion and 11q23 MLL rearrange-
ment in acute leukemias, while decreased expression is associated
with the PML-RARA and ETV6-RUNX1 gene fusions (Figure 2).
Only AKR1B1 expression has a signiﬁcant association with clinical
outcome, being associated with reduced survival in acute myeloid
leukemias and multiple myeloma (Figure 3). Recent reports have
implicatedAKRs in cellular responses to various stresses, including
promotion of hypoxia-driven HIF1a signaling, inﬂammation, and
resistance to chemotherapeutics (Dan et al., 2003; Plebuch et al.,
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FIGURE 1 | AKR expression in leukemia patients. Expression of
AKR1B1 and AKR1B10 mRNA was examined in 2093 human leukemia
patients from the Haferlach et al. (2010) study in the Oncomine database.
(A) Heatmap display of AKR1B1 (top rows) and AKR1B10 (bottom rows)
expression within the indicated leukemia types. Fold changes relative to
peripheral blood mononuclear cells (PBMCs) and p-value for that
comparison within each leukemia type are listed next to their respective
heatmaps. Numbers in parentheses next to the label of each heatmap
represent the number of patients contained within that group in this
study. (B) AKR1B1 mRNA expression in B-cell acute leukemia patients
without (blue box) and with (red box) the presence of theTCF3-PBX1
fusion gene. (C) AKR1B1 mRNA expression in acute myeloid leukemia
patients without (blue box) and with (red box) the presence of the
PML-RARA fusion gene.
2007; Yadav et al., 2007, 2009, 2011; Matsunaga et al., 2011; Zhong
et al., 2011).AKR1B1over-expressionhas also been associatedwith
an EMT-like phenotype, is implicated in colon carcinogenesis,
and notably, increased AKR1B1 protein expression and enzymatic
activity has been reported in several cancer types (Saraswat et al.,
2006; Tammali et al., 2009, 2011a,b; Ramana et al., 2010; Zablocki
et al., 2011), further suggesting that AKRs play a functional role in
tumor growth. Given the broad over-expression of AKRs, par-
ticularly AKR1B1, in human cancers and the critical processes
that they appear to regulate, AKRs have potential to be useful
therapeutic targets. AKR inhibitors have been in development for
complications related to diabetes for many years, as AKR1B1 and
the polyol pathway have been implicated in the pathogenesis of
diabetic retinopathy, nephropathy, and cataract (Makiishi et al.,
2003; Suryanarayana et al., 2004, 2007; Wolford et al., 2006; Reddy
et al., 2008, 2011; Zablocki et al., 2011). While many of these
AKR inhibitor drug development efforts have been halted due
to toxicity, they exhibit much lower toxicity than many current
cancer therapies.
AKR1B1 expression is increased by high blood glucose via NF-
κB (Yang et al., 2008), providing a potential mechanism by which
diabetes and elevated risk of developing certain cancers may be
linked. AKR1B1 and the polyol pathway also contribute to hyper-
glycemic pseudohypoxia, which one could imagine linking the
Warburg effect to tumor angiogenesis through HIF1a and per-
haps bolstering neovascularization at oxygen tensions that would
not normally promote it. Consistent with this, VEGF has been
linked to diabetic retinopathy and nephropathy (Aiello et al.,
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AKR1B1 Expression by Gene Fusion Status in Leukemias
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1. Andersson et al, Leukemia, 2007
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3. Balgobind et al, Haematologica, 2007
4. Bhojwani et al, Blood, 2006
5. Bhojwani et al, Journal of Clinical Oncology, 2008
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7. Carlo et al, Blood, 2005
8. De et al, Haematologica, 2005
9. Debernardi et al, Genes Chromosomes Cancer, 2003
10. Fine et al, Blood, 2004
11. Gutierrez et al, Leukemia, 2005
12. Haferlach et al, Journal of Clinical Oncology, 2010
13. Kirschner-Schwabe et al, Clinical Cancer Research, 2006
14. Oshima et al, Leukemia, 2003
15. Ross et al, Blood, 2003
16. Tsutsumi et al, Cancer Research, 2003
17. Valk et al, New England Journal of Medicine, 2004
18. Wouters et al, Blood, 2009
19. Yeoh et al, Cancer cell, 2002
FIGURE 2 | AKR1B1 expression by gene fusion status in leukemia
patients. AKR1B1 mRNA expression in leukemia patients with speciﬁc
gene fusions and chromosomal rearrangements was compared to
corresponding leukemia patients without the fusion across all leukemia
types and for all such events where Oncomine contained multiple
studies with such data. The heatmaps represent the relative expression
in patients with the indicated fusions compared to those without, with
red indicating over-expression in patients bearing the fusion and blue
under-expression. Median ranks and p-values consider all indicated
studies simultaneously.
1994; Cha et al., 2000; Ozaki et al., 2000), perhaps downstream
of AKR1B1-driven pseudohypoxic effects. Intriguingly, patients
with Von Hippel–Lindau disease often develop retinal angiomas
and kidney tumors, suggesting that VHL-associated malignancies
and diabetic complications may differ primarily by the degree of
HIF1a and/or VEGF-dysregulation present. It is possible that dia-
betics are effectively primed to promote tumorigenesis by virtue
of an already abnormally high level of hypoxia/HIF1a signaling.
In light of all the signs pointing to the involvement of AKRs in
human cancers, we hypothesize that AKRs are functionally linked
to cancer progression, if not initiation as well.We also propose that
AKR inhibitors would have value as cancer therapeutics in cancers
that typically feature AKR over-expression, especially in the case
of AKR1B1.
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FIGURE 3 | AKR gene expression and clinical outcome.The relationship
between AKR1B1 and AKR1B10 mRNA expression and clinical outcomes
were examined using the Oncomine database. (A) Comparison of AKR1B1
expression in acute myeloid leukemia patients who were alive (blue boxes)
and dead (red boxes) at 1 year post diagnosis. Individual p-values are indicated
within each box plot and the p-value and median gene rank for all three
studies is at the right of the panel. (B) Comparison of AKR1B1 expression in
multiple myeloma patients who were alive (blue boxes) and dead (red boxes)
at 1 year post diagnosis. Individual p-values are indicated within each box plot
and the p-value and median gene rank for all three studies is at the right of
the panel. (C) AKR1B10 expression relative to clinical outcome in liver cancer
and squamous cell lung cancer. Colored boxes are a heatmap-style
representation of AKR1B10 expression in patients dead relative to those alive
at 3 years post diagnosis, with blue indicating under-expression and red
over-expression. Median rank and p-value for this panel considers all indicated
studies simultaneously.
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